Clinical Trials Logo

Acute Myocardial Infarction clinical trials

View clinical trials related to Acute Myocardial Infarction.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06260085 Completed - Clinical trials for Acute Myocardial Infarction

Effect of Listening to Relatives' Voice Recordings on Chest Pain, Anxiety, and Depression in Coronary ICU Patients

Start date: June 4, 2022
Phase: N/A
Study type: Interventional

The aim of the study was to evaluate the effect of listening to the voice recordings of relatives of patients with acute myocardial infarction (AMI) who were treated in the coronary intensive care unit on chest pain, anxiety and depression parameters of the patients. Methods In the study, which was conducted as a randomised, controlled, experimental study, voice recordings of the family members of the patients were created and played to the patients through a music pillow. The study was carried out with 60 patients, 30 experimental and 30 control groups. Three tests were applied to the patients 15 minutes before, 15 and 30 minutes after the application. The data of the study were collected using the "Patient Introduction Form", "Hospital Anxiety Depression Scale", "Visual Analogue Scale" and "Patient Follow-up Form".

NCT ID: NCT06186713 Completed - Clinical trials for Pulmonary Hypertension

Pulmonary Hypertension on Prognosis of Acute Myocardial Infarction Patients With Reduced Left Ventricular Function

STIMULATE
Start date: March 30, 2023
Phase:
Study type: Observational

Pulmonary hypertension (PH) has a negative effect on acute myocardial infarction (AMI) patients and appears to be closely associated with reduced left ventricular function. However, its impact on AMI patients with reduced left ventricular function remains unclear. This retrospective study included AMI patients with reduced left ventricular function to investigate the prognostic value of PH in this specific type of patient. Meanwhile, a nomogram would be established basing on the identified independent risk factors, hoping to provide a novel risk stratification for them.

NCT ID: NCT06059079 Completed - Clinical trials for Acute Myocardial Infarction

Using Higher Cut-off Values to Diagnose Acute Myocardial Infarction in Patients With Elevated Hs-cTnT Concentrations

Start date: January 1, 2015
Phase:
Study type: Observational

High-sensitive cardiac troponin T (hs-cTnT) is a cornerstone for diagnosing acute myocardial infarction (AMI). However, it is often challenging to diagnose AMI in patients with elevated hs-cTnT before a rise or fall of hs-cTnT can be observed. The elevations of hs-cTnT are caused not only by AMI, but also by other cardiac or even non-cardiac diseases. Thresholds above the 99th percentile have been proposed to improve the specificity and to accelerate the rule in of myocardial infarction. This study aimed to find a more accurate cut-off value to rule in AMI in patients with elevated hs-cTnT.

NCT ID: NCT06034054 Completed - Clinical trials for Coronary Artery Disease

Acute Coronary Syndrome and Nurse Counselling

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to examine in patients with acute coronary syndrome. The main questions it aims to answer are: - Does nurse counseling affect quality of life? - Does nurse counseling affect functional capacity? - Does nurse counseling affect knowledge, attitudes and beliefs about syndromes? Participants will be trained using the training booklet, and nursing counseling will then be provided for six months. If there is a comparison group: Researchers will compare with the control group to see if the nurse counseling has had an effect.

NCT ID: NCT05984134 Completed - Clinical trials for Acute Myocardial Infarction

Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction

Start date: July 15, 2022
Phase: Phase 2
Study type: Interventional

A multicenter randomized double-blind placebo parallel control design was used in this study. The 90 participants were randomly assigned to placebo, 0.5μg/kg dose group, and 1.0μg/kg dose group in a ratio of 1:1:1. After randomization, subjects received the trial drug or placebo intravenously within 12 hours and on days 2 to 7 after PCI. The patients were observed 90 days after PCI.

NCT ID: NCT05974397 Completed - Clinical trials for Acute Myocardial Infarction

Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan

Start date: September 30, 2021
Phase:
Study type: Observational

This was a retrospective study using the Taiwan's National Health Insurance Research Database (NHIRD). The study employed two study designs for different purposes as follows: - A cross-sectional analysis was conducted to explore the annual incidence trends. - A longitudinal cohort study was conducted to assess baseline characteristics, treatment patterns, long-term healthcare utilization, and cause-specific mortality among incident AMI patients. In each part, the study was conducted for AMI, and separately for ST-segment elevation and non-ST- segment elevation myocardial infarction (STEMI and NSTEMI)

NCT ID: NCT05843006 Completed - Clinical trials for Acute Myocardial Infarction

Sweat Analysis as Prognosticator After Heart Attack

SWEATHEART
Start date: March 21, 2022
Phase:
Study type: Observational [Patient Registry]

This study characterizes non-invasive body inflammation response in sweat and blood of patients suffering from acute myocardial infarction and explores the potential of non-invasive sweat analysis a an innovative approach for predicting patient outcome.

NCT ID: NCT05511649 Completed - Clinical trials for Acute Myocardial Infarction

New-Onset Atrial Fibrillation Complicating Acute Myocardial Infarction in China

NOAFCAMI-China
Start date: March 1, 2023
Phase:
Study type: Observational

To investigate the prognostic impacts of the atrial fibrillation burden (AFb) in acute myocardial infarction (AMI) patients who developed paroxysmal new-onset atrial fibrillation (NOAF) during the index AMI hospitalization.

NCT ID: NCT05485818 Completed - Clinical trials for Acute Myocardial Infarction

Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction

Start date: November 23, 2020
Phase: Phase 2
Study type: Interventional

A multicenter randomized double-blind placebo parallel control design was used in this study.60 subjects eligible for inclusion will be randomly assigned to either a low-dose (0.25ug/kg) medium-dose (0.5ug/kg) high-dose (2.0ug/kg) experimental drug group or a control group (placebo) at a ratio of 1:1:1:1.After randomization, subjects received the experimental drug or placebo once a day, intravenously, on day 2 to 7, 12 hours and 4 hours after PCI.Ninety days after PCI were observed.

NCT ID: NCT05419635 Completed - Atrial Fibrillation Clinical Trials

A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function

Start date: June 14, 2022
Phase: Phase 1
Study type: Interventional

Researchers are looking for a better way to prevent the formation of blood clots in people who have or have had: - an irregular and often rapid heartbeat - a blocked blood flow to the heart - a blocked or reduced blood flow to a part of the brain. When a blood clot forms in the body in patients with the above conditions, it may block vessels of the heart, the brain and/or other parts of the body. This may lead to heart attack, stroke and other serious complications. Blood clots are formed in a process known as coagulation. This is a complex series of steps that must occur in a specific sequence. Medications are already available to prevent the formation of blood clots. They work by interrupting one or more of the coagulation steps and are therefore known as anticoagulants. They decrease the risk of the above-mentioned complications. The study treatment asundexian works by blocking a very specific step in the blood clotting process, the activation of a protein called Factor XIa. Due to its very specific action that is not thought to be involved in the main blood clotting steps needed to stop bleeding (e.g. like from a cut finger), asundexian is expected to reduce the risk of bleeding that is still seen with existing anticoagulants. Since people who need an anticoagulant may also have liver problems, information on asundexian use in this group is needed. The main purpose of this study is to learn how asundexian moves into, through and out of the body in participants with a mild or moderate reduction in liver function compared to participants with normal liver function who are similar in age, weight, and gender. To answer this question, researchers will measure - the average highest level of asundexian in the blood (also referred to as Cmax) - the average total level of asundexian in the blood (also referred to as AUC). that were reached after intake of a single tablet of asundexian. The researchers will compare these data between participants with reduced liver function and matched participants with normal liver function to look for differences. Each participant will be in the study for up to 4 weeks. Participants will stay in-house for 6 days, starting the day before taking asundexian. In addition, two visits to the study site are planned. During the study, the doctors and their study team will: - do physical examinations - check vital signs - take blood and urine samples - examine heart health using an electrocardiogram (ECG) - ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.